Veru Inc. Nasdaq:VERU | --- | --- | --- | --- | |------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | Biopharmaceutical Company Focused on COVID-19 and Oncology | | | | | Veru Corporate Presentation H.C. Wainwright Global Investment Conference May 23-26, 2022 | | | | Forward looking statements The statements in this release that are not historical facts are "forward-looking statements" as that term is defined in the Private Securitie ...

Call End: 09:01 Veru Inc. (NASDAQ:VERU) Q2 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Howerton - Jefferies Leland Gershell - Oppenheimer Yi Chen - ...

FORM 10-Q (Mark One) Commission File Number 1-13602 Veru Inc. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Wisconsin 39-1144397 (State of Incorporation) (I.R.S. Employer Identification No.) 2916 N. Miami Avenue, Suite 1000, Miami, FL 33127 (Address of Principal Executive Offices) (Zip Code) N/A (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of ...

Veru Inc. Nasdaq:VERU | --- | --- | --- | --- | |-------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Biopharmaceutical Company Focused on COVID-19 and Oncology | | | | | Veru Corporate Presentation May 2022 | | | | Forward looking statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of forward-looking words o ...

Veru Inc. Nasdaq:VERU | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Oncology Biopharmaceutical Company Focused on Breast Cancer and Prostate Cancer | | | | | Veru Corporate Presentation Oppenheimer 32nd Annual Healthcare Conference March 15-17, 2022 | | | | Forward looking statements This communication contains forward-looking statements within the meaning of the Private Secu ...

Veru Inc. (NASDAQ:VERU) Q1 2022 Earnings Conference Call February 9, 2022 8:00 AM ET Company Participants Samuel Fisch - Executive Director of Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Leland Gershell - Oppenheimer & Co. Christopher Howerton - Jefferies LLC Yi Chen - H.C. Wainwright & Co., LLC K ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number 1-13602 Veru Inc. (Exact Name of Registrant as Specified in its Charter) Wisconsin 39-1144397 (State of Incorporation) (I.R.S. Employer Identification No.) 48 NW 25 Street, Suite 102, Miami, FL 33127 (Address of Principal Executive Offices) (Zip Code) 305-509-6897 (Registrant's Telephone Number, Including Area Code) N/A (Former Name, Former Address and Former Fiscal Year, if Changed Since Last ...

Veru, Inc. (NASDAQ:VERU) Q4 2021 Results Earnings Conference Call December 2, 2021 8:00 AM ET Company Participants Sam Fisch - Executive Director of Investor Relations and Corporate Communications. Mitchell Steiner - Chairman, President & CEO Michele Greco - CFO & Chief Administrative Officer Gary Barnette - Chief Scientific Officer Michael Purvis - Executive Vice President, General Counsel & Corporate Strategy Conference Call Participants Brandon Folkes - Cantor Fitzgerald Leland Gershell - Oppenheimer Yi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-13602 Veru Inc. (Name of registrant as specified in its charter) | Wisconsin 39-1144397 | | | --- | --- | | (State or other jurisdiction ...

Financial Highlights - Veru's FY2020 net revenues were $426 million[5] - Veru's FYTD 2021 net revenues reached $456 million with a gross profit of $356 million[5] - The sexual health business generated $328 million in operating income FYTD 2021[5] - FC2 Female Condom's FY2020 net revenues were $406 million, and FYTD 2021 net revenues were $448 million[5] - Veru's cash reserves stood at $1232 million as of June 30, 2021[5] Drug Pipeline & Clinical Trials - Sabizabulin (32mg) is in Phase 3 clinical trials for metastatic castration and AR targeting agent resistant prostate cancer[10, 11] - VERU-100 is in Phase 2 clinical trials for hormone-sensitive advanced prostate cancer[10, 11] - Enobosarm is planned for a Phase 3 trial in Q3 2021 for AR+ER+HER2- metastatic breast cancer (3rd line metastatic)[10, 44] - Sabizabulin (9mg) is in Phase 3 clinical trials for hospitalized COVID-19 patients at high risk for ARDS[4, 10, 94] - TADFIN™ for BPH has a PDUFA date in December 2021[4, 100]